Commercialization Phase II

crunchkingofprussiaΒιοτεχνολογία

6 Δεκ 2012 (πριν από 4 χρόνια και 6 μήνες)

136 εμφανίσεις

Commercialization of Publicly
Funded R&D
:


Mechanisms and Approaches within U.S.
Agencies & S&T Organizations Abroad


Carlos E. Gutierrez

Chief Strategy Officer

Larta Institute


June 2011

Our Mission

To vastly improve the transition of
scientific and technological
breakthroughs from the lab to the
marketplace, and to help government
-
funded entrepreneurs/innovators create
self
-
sustainable enterprises

2

Confidential. Copyright Larta Institute 2011. All rights reserved

US and Global Clients/Partners

3

About Larta


Founded 1993 as a public

private
partnership


Non
-
profit, private corporation


Innovation policy advice for both national and
regional
economies around the world to build
strong ecosystems


Design and execution of programs (
for US and
Global Partners
) to accelerate the market
readiness of early stage enterprises:


Commercialization from emerging R&D
-
based enterprises


Commercialization Assistance Programs (CAPs)


University technology transfer


Technology Transfer Programs (TTPs)


Foster strategic relationships with capital
providers and industry
partners

4

Background

Core Services

5

SBIR


Started in 1982


All 11 agencies participate


2.5 % of agency R&D budget


Currently $2 Billion


$14 Billion Awarded via 50,000
grants since Inception


The US Experience
-

The SBIR & STTR Programs

Funding to Support R&D Activities

STTR


Started in 1992


The largest 5 agencies participate


DOD, DOE, NIH, NASA & NSF


0.3 % of agency R&D budget


Currently $100 Million


Small business must have
partnership with non
-
profit research
institution


university or research center



531 Publicly traded
companies


Qualcomm
,
Millenium
, Amgen, JDS
Uniphase etc.


1,200 M&A deals to date


552 current VC
-
funded
companies

6

A Three
-
Phase Program


Grants $100K


$300K


6


12 months


Support exploration of
technical merit or feasibility


Grants from $500K
-

$3M


12 to 24 Months


Refinement of technology


No more government grants


Private funding


Exit: sales, IPO, licensing, etc.


Phase I: Start up Phase

Phase III:
Commercialization

Phase II: Expand idea, find
commercial outlets

7

Challenge:


Agencies realized that they only provided support to one
piece of the equation (R&D work), but had no instrument to
facilitate the market readiness/awareness/connections for
innovations headed by a PI (principal investigator) with a
scientific/research background.

Solution:


Agencies contract with external partner organizations to
design and implement Commercialization Assistance
Programs (CAPs) for their grantees.

The US Experience
-

The SBIR & STTR Programs

Mechanism to support commercialization of
publicly
-
funded R&D

Confidential. Copyright Larta Institute 2011. All rights reserved

Objective of Larta CAPs

Larta mentors emerging companies, and connects them
to the right people, capital and resources.


Prepare tech
-
based enterprises to cross the Valley of Death

8

9

Provide SBIR/STTR grantees with
focused assistance to refine their
business models, accelerate the
commercialization of their IP, and foster
connections with investors/partners

Commercialization Assistance
Programs (CAPs)


A Virtual Model


Larta designs and manages CAPs for 5 of the largest
SBIR/STTR programs of the federal agencies:

NIH, USDA, NSF, TATRC (US Army) and DOE

Confidential. Copyright Larta Institute 2011. All rights reserved

Larta U.S. CAPs

National Institutes of Health


80+ SBIR Phase II companies each year


Medical devices, pharmaceuticals, diagnostics, healthcare IT, biotech, etc.


18 months of tracking after the program

National Science Foundation


250+ SBIR/STTR Phase I companies each year


Industrial technology,
c
leantech
, energy, advanced materials/nanotechnology,
electronics/IT, chemical
-
based technologies, etc.

US Department of Agriculture


40+
SBIR Phase II companies each year


Food and nutrition, precision agriculture, animal health, plant science, biofuels, etc.

US Army
-

TATRC


25
SBIR Phase II companies each year


Healthcare IT, Mobile Health, robotics, simulation software, etc.

US Department of Energy


125 SBIR Phase II grant applications reviewed each year, with recommendations
provided for funding grants


Energy efficiency, renewable energy, wind, solar, green materials, sensors,
generation, etc.


10

Confidential. Copyright Larta Institute 2011. All rights reserved

Anatomy of a CAP: NIH
-
CAP

Case Study

11


Funded
by NIH, developed and managed by Larta Institute to assist
SBIR Phase II NIH awardees with
commercialization. Since 2004.


Designed
to help small life science and healthcare companies to
develop their commercial “profile” and transition their SBIR
-
funded
technologies into the
marketplace


Competitive process: 80 companies selected from among 250+ eligible
ventures


The
company’s “decision maker”/CEO is encouraged to participate in
the CAP as the
CAP
-
Leader


Sponsored (financed) by NIH.


10 month program (virtual and face
-
to
-
face).


Combination of:


Intense 1:1 mentoring by Larta Principal Advisor


Feedback Sessions with external 3rd party experts (investors, industry, IP
strategists, regulatory specialists, etc.)


Boston, DC, Los Angeles


Strategic Introductions through Larta Industry Advisory Boards (IAB)

Confidential. Copyright Larta Institute 2011. All rights reserved



Larta Industry Advisory Boards

(IAB)

Chemical/Materials/
Cleantech

Ashland Corp.

BASF

Boeing

Chisso Corp.

Dow Chemical Co.

Honda Strategic Venturing

Procter & Gamble

Sekisui Integrated
Research

SEMPRA Energy

Sharp Corporation

Texas Instruments

Schlumberger

3M

Electronics/IT/
Software

Boeing

Honda Strategic
Venturing

Philips Healthcare

Sharp Corporation

TechNavi, LLC

Texas Instruments

Schlumberger

Motorola

Life Science

Abbott

Allergan

Bayer

BD Ventures

Biogen IDEC

Boehringer Ingelheim

Genentech

Genzyme

Johnson & Johnson

Life Technologies

Medtronic

Merck

Novo Nordisk

Pfizer

Philips Health care

RCT Bioventures

Siemens Ventures

Takeda

Agriculture

Finistere

Ventures
(Chair)

BASF

Bayer Crop Science

Cargill

ADM

Dow Agrosciences

Monsanto

Nelson Gibson (formerly
with John Deere)

Nestle

Novus International

Pioneer Hi
-
Bred

Syngenta

12

Confidential. Copyright Larta Institute 2011. All rights reserved

NIH
-
CAP
Case
Study

Deliverables

13


The development of a
Market
-
Driven Presentation
. The presentation will
convey the company’s value proposition and will embody and address the
critical components of a market entry strategy: technology, Intellectual
property, markets and market need (problem), management,
manufacturing/business model and adoption issues, and strategic
alliances.



A
2
-
3
-
page
Commercialization Strategy Report

(CSR)

document which
includes a
Barriers to Commercialization

document, a
Competitive Matrix
,
and a

Commercialization Roadmap

or schedule of budgetary and operating
milestones. The Commercialization Strategy Report will summarize
recommendations and next steps that will help the company meet the
commercialization objectives that were outlined earlier.


Confidential. Copyright Larta Institute 2011. All rights reserved

NIH
-
CAP 2010

Companies by Industry Sectors

14

Biotechnology, 107, 16%

Diagnostics, 86, 13%

Healthcare IT, 90, 14%


Medical Device, 176, 27%

Pharmaceuticals, 68, 11%

Other*, 124, 19%

Total

Biotechnology
Diagnostics
Healthcare IT
Medical Device
Pharmaceuticals
Other*
Confidential. Copyright Larta Institute 2011. All rights reserved

Metrics: NIH
-
CAP Case Study


Mentored over 600 NIH
-
funded
companies


$397 million raised by
companies attributable to Larta
impact*


10 acquisitions (8 companies, 2
technologies)



302 deals made


500+ initial proposals & term
sheets created


1,800 CDAs signed


3,600 meetings with investors &
partners arranged

NIH
-
CAP: 2004
-
Current

Additional Partnership &
Deal
-
Related Activity

15

* http://grants.nih.gov/grants/funding/cap/success_data_NIH_CAP.pdf

Confidential. Copyright Larta Institute 2011. All rights reserved

Larta
-

Global Bridge Initiatives


Defined: CAPs designed for innovation agencies/S&T
organizations around the world


Aligned with innovation policy objectives and integrated
with key stakeholders
(universities/research institutes, industry,
economic development agencies)


Focused on internationalization of early stage R&D
-
based ventures and developing linkages to U.S. partners


Strong component of technology transfer for benefit of
the regional partner


Supports
sustainability


Builds
local capacity for regions to manage their own commercialization
efforts


Linkage to Larta Institute as
a
ongoing U.S.
-
based
partner



16

Confidential. Copyright Larta Institute 2011. All rights reserved



Carlos E. Gutierrez

Chief

Strategy

Officer

cgutierrez@larta.org



606 S. Olive Street, Suite 650

Los Angeles, CA 90014

ph
: 213.538.1453

fx
: 213.622.6230

www
.larta.org



17